Medical Disclaimer: This information is educational and not a substitute for medical advice
19,28,30 Further research is needed to clarify the role of GLP-1 agonists in cognitive disorders due to variability in study designs, patient populations, and treatment regimens that may contribute to differing outcomes
SSZ and RAM provided senior author input in the design of the study and review of the manuscript, and UA oversaw the study development, manuscript writing, provided senior author review of the manuscript and is the guarantor of this work
State Health Plan spending on GLP-1 drugs such as Wegovy rose from about $3 million per month in around 2021-2022 to more than $14 million per month in 2023, making In 2023, the drugs accounted for roughly 10% of the $1 billion the plan spends on all prescription drugs
Not ill, just not quite themselves
But in 2016, the LEADER trial revealed a new dimension: fewer cardiovascular events in patients with type 2 diabetes